

## PRESS RELEASE

**EOS imaging Announces a Co-marketing Agreement with Medtronic Japan***Partnership to accelerate EOS's adoption in the Japanese market*

**Paris, April 6, 2016** - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today a co-marketing agreement with Medtronic Japan. This exclusive partnership will enable Medtronic Japan's sales force to market EOS imaging's platform of products to its customers thereby facilitating the adoption of EOS in the Japanese market.

With the EOS platform, spine surgeon customers will have the ability to preoperatively and postoperatively visualize a patient's spine and lower limbs in a weight-bearing position in 2D and 3D. This allows surgeons to access valuable and precise anatomical information and support their diagnosis, therapeutic strategy, and operative plan with relevant images and patient data. The imaging equipment and associated software of the EOS platform supports the patient care pathway with unique 2D/3D data at a dose that's as low as reasonably achievable.

The co-marketing agreement is exclusive for the Japanese market and establishes a systematic way of marketing Medtronic's technologies with the EOS imaging platform through marketing collateral, trade show booths, visiting surgeon programs, symposiums and joint sales efforts. Terms of the agreement were not disclosed.

Marie Meynadier, CEO of EOS imaging said, *"Japan is a very important market that we are pleased to address with Medtronic. Our corporate missions and solutions are very complementary, and we expect excellent outcomes from the synergies and benefits of partnering. The combination of Medtronic's portfolio with our unique low-dose imaging and 3D-planning solutions will provide patients in Japan with innovative solutions for the treatment of their spinal pathologies."*

For more information, please visit [www.eos-imaging.com](http://www.eos-imaging.com).

**EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.**

EOS imaging is listed on Compartment C of Euronext Paris  
ISIN: FR0011191766 – Ticker: EOSI



**Next press release: 2015 Full-year results and 2016 First-quarter sales on April 28, 2016**



## PRESS RELEASE

### **About EOS imaging**

EOS imaging designs, develops, and markets EOS<sup>®</sup>, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan, China, and the European Union (EC). The Group posted 2015 revenues of €21.8 million and employs 107 people including an R&D team of 39 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

### **Contacts:**

#### **Anne Renevot**

CFO

Ph: +33 (0)1 55 25 61 24

[investors@eos-imaging.com](mailto:investors@eos-imaging.com)

#### **NewCap**

Financial communication and investor relations

Pierre Laurent

Ph: +33 (0)1 44 71 94 94

[eosimaging@newcap.eu](mailto:eosimaging@newcap.eu)

#### **The Ruth Group (US)**

Press relations / Joanna Zimmerman

Ph: 646-536-7006

[jzimmerman@theruthgroup.com](mailto:jzimmerman@theruthgroup.com)